Northwest Biotherapeutics reported $7.2M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agenus USD 95.28M 38.15M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Celldex Therapeutics USD 459.22M 75.44M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
Merck USD 35.02B 8.5B Mar/2026
Northwest Biotherapeutics USD 7.2M 1.04M Sep/2025
Pfizer USD 42.82B 76M Mar/2026
Plus Therapeutics USD 18.03M 2.86M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025